 |
 |
 |
 |
 |
Maryalice
>Melissa --
>
>According to the FAB group (Bennett JM, et al, J. Clin. Pathol. 1989;
>42:567-584), the incidence at which FMC7 is positive in >30% of cells in
>intermediate lymphocytic lymphoma (ie, Mantle Cell lymphoma) is 40-80%; in
>CLL, it is 10-40%.
>
>Our lab here in Scottsdale does not use FMC7; our panel resembles what Hugh
>Johnson has listed in his message earlier. We found that the addition of CD23
>sometime ago has facilitated identification of early (leukemic) presentations
>of MCL (CD5+/CD23-). These cases probably account for as many as 5-10% of our
>clonal B cell lymphoid leukemia patients. I would, however, add something to
>what Maryalice and Hugh have stated: the relative *intensity* of sIg and CD20
>expression can be extremely helpful in distinguishing between MCL and CLL. MCL
>(and other NHL) are typically bright CD20+ and bright kappa (or lambda)
>positive, while CLL shows dim/weak expression for these markers.
>
>What do some other folks have to say about panels in the workup of chronic
>lymphoid leukemias? (Randy Gascoyne? Curt Hanson?)
>
>***************************************************************
>Christopher R. Conley, MD conley.christopher@mayo.edu
>Dept. of Pathology Tel:(602)301-8021 FAX:(602)301-8372
>Mayo Clinic Scottsdale 13400 E. Shea Blvd. Scottsdale AZ 85259
Maryalice Stetler-Stevenson
Director Flow Cytometry Unit
Laboratory of Pathology, NCI, NIH
|
|
|
|
|
|
CD-ROM Vol 3 was produced by Monica M. Shively and other staff at the
Purdue University Cytometry Laboratories and distributed free of charge
as an educational service to the cytometry community.
If you have any comments please direct them to
Dr. J. Paul Robinson, Professor & Director,
PUCL, Purdue University, West Lafayette, IN 47907.
Phone: (765)-494-0757;
FAX(765) 494-0517;
Web